LIFE - aTyr Pharma posts preclinical research of ATYR2810 in lung and breast cancer at AACR21

aTyr Pharma (LIFE) announces two poster presentations at the 2021 American Association for Cancer Research ((AACR)) Annual Meeting.In animal models of non-small cell lung cancer, ATYR2810 administered therapeutically as a single agent significantly inhibited tumor growth, the company said.When administered in combination with chemotherapy, including either 5-FU or cisplatin, ATYR2810 inhibited tumor growth to a greater extent compared to either chemotherapeutic agent alone.ATYR2810 used in combination with chemotherapy or bevacizumab increased anti-tumor effects in triple-negative breast cancer model.The meeting is being held virtually April 10 – 15 and May 17 – 21, 2021.#AACR21Shares up more than 1% premarket.

For further details see:

aTyr Pharma posts preclinical research of ATYR2810 in lung and breast cancer at AACR21